法尼醇
神经退行性变
预酸化
药理学
医学
疾病
神经科学
多巴胺能
生物
帕金森病
生物化学
多巴胺
内科学
酶
作者
Areum Jo,Yunjong Lee,Tae‐In Kam,Sung-Ung Kang,Stewart Neifert,Senthilkumar S. Karuppagounder,Rin Khang,Hojin Kang,Hyejin Park,Shih-Ching Chou,Sungtaek Oh,Haisong Jiang,Deborah A. Swing,Sangwoo Ham,Sheila K. Pirooznia,George K. E. Umanah,Xiaobo Mao,Manoj Kumar,Han Seok Ko,Ho Chul Kang
标识
DOI:10.1126/scitranslmed.aax8891
摘要
promoter. Farnesol prevented dopaminergic neuronal loss and behavioral deficits via farnesylation of PARIS in PARIS transgenic mice, ventral midbrain transduction of AAV-PARIS, adult conditional parkin KO mice, and the α-synuclein preformed fibril model of sporadic PD. PARIS farnesylation is decreased in the substantia nigra of patients with PD, suggesting that reduced farnesylation of PARIS may play a role in PD. Thus, farnesol may be beneficial in the treatment of PD by enhancing the farnesylation of PARIS and restoring PGC-1α activity.
科研通智能强力驱动
Strongly Powered by AbleSci AI